drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Patient-derived T cells engineered with a chimeric antigen receptor targeting B-cell antigens; cellular immunotherapy administered sequentially after ASCT.
nci_thesaurus_concept_id
C200766
nci_thesaurus_definition
Autologous T-lymphocytes engineered to contain one or more chimeric antigen receptors (CARs) that specifically target one or more specific antigen(s).
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T lymphocytes are genetically engineered to express a chimeric antigen receptor that recognizes B-cell antigens in an HLA-independent manner. Upon antigen binding, CAR signaling domains activate the T cells, driving proliferation, cytokine release, and targeted cytotoxic killing of malignant B cells.
drug_name
Autologous CAR-T cells
nct_id_drug_ref
NCT07059741